KIT Mutations in Mastocytosis and Their Potential as Therapeutic Targets

Immunology and Allergy Clinics of North America

Volumn 26, Issue 3, 2006, Pages 575-592

  Gotlib, Jason ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; AD 38; ANTINEOPLASTIC ANTIBIOTIC; AP 23848; CLADRIBINE; DASATINIB; DENILEUKIN DIFTITOX; GEFITINIB; IMATINIB; IMD 0354; MIDOSTAURIN; MONOCLONAL ANTIBODY; NILOTINIB; OSI 930; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; STEM CELL FACTOR; SU 11652; SU 11654; SU 11655; SU 4984; SU 5614; SU 6577; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; EOSINOPHILIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE FUSION; GENE MUTATION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; MAST CELL; MASTOCYTOSIS; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME;

ANIMALS; HUMANS; MASTOCYTOSIS, SYSTEMIC; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 33747336257     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2006.05.003     Document Type: Review

References (103)

1. Yarden Y., Kuang W.-J., Yang-Feng T., et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 11 6 (1987) 3341-3351
2. Reilly J.T. Class III receptor tyrosine kinases: role in leukaemogenesis. Br J Haematol 116 4 (2002) 744-757
3. Heinrich M.C., Blanke C.D., Druker B.J., et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20 6 (2002) 1692-1703
4. Rousset D, Agnes F, Lachaume P, et al. Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulin-like domains. J Mol Evol 1995;41(4):421-9.
5. Ogawa M., Matsuzaki Y., Nishikawa S., et al. Expression and function of c-kit in hemopoietic progenitor cells. J Exp Med 174 1 (1991) 63-71
6. Natali P.G., Nicotra M.R., Sures I., et al. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 52 22 (1992) 6139-6143
7. Nocka K., Majumder S., Chabot B., et al. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice-evidence for an impaired c-kit kinase in mutant mice. Genes Dev 3 6 (1989) 818-826
8. Huizinga J.D., Thuneberg L., Kluppel M., et al. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373 6512 (1995) 347-349
9. Williams D.E., Eisenman J., Baird A., et al. Identification of a ligand for the c-kit proto-oncogene. Cell 63 1 (1990) 167-174
10. Zsebo K.M., Williams D.A., Geissler E.N., et al. Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63 1 (1990) 213-224
11. Huang E., Nocka K., Beier D.R., et al. The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 63 1 (1990) 225-233
12. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 31 10 (1999) 1053-1074
13. Brizzi M.F., Dentelli P., Rosso A., et al. STAT protein recruitment and activation in c-Kit deletion mutants. J Biol Chem 274 24 (1999) 16965-16972
14. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 5350 (1998) 577-580
15. Lux M.L., Rubin B.P., Biase T.L., et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156 3 (2000) 791-795
16. Gari M., Goodeve A., Wilson G., et al. c-Kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 105 4 (1999) 894-900
17. Beghini A., Peterlongo P., Ripamonti C.B., et al. C-Kit mutations in core binding factor leukemias. Blood 95 (2000) 726-727
18. Tian Q., Frierson H.F.J., Krystal G.W., et al. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 154 6 (1999) 1643-1647
19. Hongyo T., Li T., Syaifudin M., et al. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res 60 9 (2000) 2345-2347
20. Furitsu T., Tsujimura T., Tono T., et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92 4 (1993) 1736-1744
21. Nagata H., Worobec A.S., Oh C.K., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 92 23 (1995) 10560-10564
22. Longley B.J., Tyrrell L., Lu S.Z., et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 12 3 (1996) 312-314
23. Longley Jr. B.J., Metcalfe D.D., Tharp M., et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 96 4 (1999) 1609-1614
24. O'Brien S., Tefferi A., and Valent P. Chronic myelogenous leukemia and myeloproliferative disease. Hematology (Am Soc Hematol Educ Program) 1 (2004) 46-62
25. Akin C. Clonality and molecular pathogenesis of mastocytosis. Acta Haematol 114 1 (2005) 61-69
26. Chian R., Young S., Danilkovitch-Miagkova A., et al. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-KIT mutant. Blood 98 5 (2001) 1365-1373
27. Shivakrupa R., Bernstein A., Watring N., et al. Phosphatidylinositol 3′-kinase is required for growth of mast cells expressing Kit catalytic domain mutant. Cancer Res 63 15 (2003) 4412-4419
28. Piao X., Paulson R., Van Der Geer P., et al. Oncogenic mutation in the KIT receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc Natl Acad Sci USA 93 25 (1996) 14665-14669
29. Longley B.J., Reguera M.J., and Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 25 7 (2001) 571-576
30. Irusta P.M., Luo Y., Bakht O., et al. Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor beta receptor. J Biol Chem 277 41 (2002) 38627-38634
31. Gotlib J., Cools J., Malone J.M., et al. The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103 8 (2004) 2879-2891
32. Gilliland D.G., and Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 100 5 (2002) 1532-1542
33. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 14 (2001) 1031-1037
34. Druker B.J., Sawyers C.L., Kantarjian H., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344 14 (2001) 1038-1042
35. Apperley J.F., Gardembas M., Melo J.V., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347 7 (2002) 481-487
36. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 13 (2003) 1201-1214
37. Rubin B.P., Schuetze S.M., Eary J.F., et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20 17 (2002) 3586-3591
38. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 7 (2002) 472-480
39. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 5607 (2003) 708-710
40. Ma Y., Zeng S., Metcalfe D.D., et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99 5 (2002) 1741-1744
41. Zermati Y., De Sepulveda P., Féger F., et al. Effect of the tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 22 5 (2003) 660-664
42. Frost M.J., Ferrao P.T., Hughes T.P., et al. Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 1 12 (2002) 1115-1124
43. Akin C., Brockow K., D'Ambrosio C., et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 31 8 (2003) 686-692
44. Pardanani A., Elliott M., Reeder T., et al. Imatinib for systemic mast-cell disease. Lancet 362 9383 (2003) 535-537
45. Pardanani A., Brockman S., Reeder T., et al. Treatment-relevant molecular classification of systemic mast cell disease associated with eosinophilia. Blood 102 11 (2003) 918a
46. Rondoni M., Soverini S., Malagola M., et al. Imatinib seems to be ineffective in patients with systemic mastocytosis carrying the Asp816Val c-kit mutation. Blood 102 11 (2003) 335b-336b
47. Hennessy B., Giles F., Cortes J., et al. Management of patients with systemic mastocytosis: review of the M.D. Anderson Cancer Center Experience. Am J Hematol 77 3 (2004) 209-214
48. Musto P., Falcone A., Sanpaolo G., et al. Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis. Leuk Res 28 4 (2004) 421-422
49. Jabbour E., Kantarjian H., Verstovsek S., et al. Imatinib mesylate for patients (pts) with hypereosinophilic syndrome (HES) and systemic mastocytosis (SM): a phase II trial. Blood 104 11 (2004) 271b
50. Akin C., Funo C., Yavuz A.S., et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103 8 (2004) 3222-3225
51. Zhang L.Y., Smith M.L., Schultheis B., et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 30 4 (2006) 373-378
52. Schaller J.L., and Burkland G.A. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 3 5 (2001) 9
53. Gleich G.J., Leiferman K.M., Pardanani A., et al. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359 9317 (2002) 1577-1578
54. Ault P., Cortes J., Koller C., et al. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 26 9 (2002) 881-884
55. Pardanani A., Reeder T., Porrata L.F., et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 101 9 (2003) 3391-3397
56. Cortes J., Ault P., Koller C., et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101 12 (2003) 4714-4716
57. Klion A.D., Noel P., Akin C., et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101 12 (2003) 4660-4666
58. Tefferi A., Pardanani A., and Li C.Y. Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities?. Blood 102 8 (2003) 3073-3074
59. Tefferi A., Lasho T.L., Brockman S.R., et al. FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica 89 7 (2004) 871-873
60. Lemery S.J., Robyn J.A., McCoy P., et al. Lineage analysis of the FIP1L1-PDGFRa fusion gene in myeloproliferative hypereosinophilic syndrome. Blood 104 11 (2004) 670a-671a
61. Pardanani A., Ketterling R.P., Brockman S.R., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood 102 9 (2003) 3093-3096
62. Pardanani A., Brockman S.R., Patemoster S.F., et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104 10 (2004) 3038-3045
63. Fabbro D., Ruetz S., Bodis S., et al. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Res 15 1 (2000) 17-28
64. Weisberg E., Boulton C., Kelly L.M., et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1 5 (2002) 433-443
65. Stone R.M., DeAngelo D.J., Klimek V., et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105 1 (2005) 54-60
66. Stone R.M., Fischer T., Paquette R., et al. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML. Blood 106 11 (2005) 121a-122a
67. Chen J., DeAngelo D.J., Kutok J.L., et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in the treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA 101 40 (2004) 14479-14484
68. Cools J., Stover E.H., Boulton C.L., et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRA-induced myeloproliferative disease. Cancer Cell 3 5 (2003) 459-469
69. Growney J.D., Clark J.J., Adelsperger J., et al. Activation mutations of human c-Kit resistant to imatinib are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106 2 (2005) 721-724
70. Gotlib J., Berubé C., Growney J.D., et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106 8 (2005) 2865-2870
71. Casteran N., De Sepulveda P., Beslu N., et al. Signal transduction by several KIT juxtamembrane domain mutations. Oncogene 22 30 (2003) 4710-4722
72. Ning Z.Q., Li J., and Arceci R.J. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit mediated cytokine-independent survival and proliferation in human leukemia cells. Blood 97 11 (2001) 3559-3567
73. Gleixner K.V., Mayerhofer M., Aichberger K.J., et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison of AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107 2 (2006) 752-759
74. Sonneck K., Mayerhofer M., Gleixner K.V., et al. Detection of activated STAT5 in neoplastic mast cells in patients with systemic mastocytosis: role of c-kit D816V. Blood 106 11 (2005) 981a
75. Shah N.P., Tran C., Lee F.Y., et al. Overridng imatinib resistance with a novel ABL kinase inhibitor. Science 305 5682 (2004) 399-401
76. D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in the majority of patients with systemic mastocytosis. Blood 108 1 (2006) 286-291
77. Schittenhelm M.M., Shiraga S., Schroeder A., et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66 1 (2006) 473-481
78. Schindler T., Bornmann W., Pellicana P., et al. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289 5486 (2000) 1938-1942
79. Nagar B., Bornmann W.G., Pellicana P., et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62 15 (2002) 4236-4243
80. Mol C.D., Lim K.B., Sridhar V., et al. Structure of a c-kit product complex reveals the basis for kinase transactivation. J Biol Chem 278 34 (2003) 31461-31464
81. Mol C.D., Fabbro D., and Hosfield D.J. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors. Curr Opin Drug Discov Dev 7 5 (2004) 639-648
82. Mol C.D., Dougan D.R., Schneider T.R., et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279 30 (2004) 31655-31663
83. Shah N.P. Loss of response to imatinib: mechanisms and management. Hematology (Am Soc Hematol Educ Program) (2005) 183-187
84. Weisberg E., Manley P.W., Breitenstein W., et al. Characterization of AMN107, a selective inhibitor of native and mutant bcr-abl. Cancer Cell 7 2 (2005) 129-141
85. Verstovsek S., Akin C., Giles F.J., et al. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Blood 106 11 (2005) 985a
86. Von Bubnoff N., Gorantla S.H.P., Kancha R.K., et al. The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 19 9 (2005) 1670-1671
87. Corbin A.S., Demehri S., Griswold I.J., et al. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood 106 1 (2005) 227-234
88. Corbin A.S., Griswold I.J., La Rosée P., et al. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood 104 12 (2004) 3754-3757
89. Liao A.T., Chien B.B., Shenoy N., et al. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 100 2 (2002) 585-593
90. Carter T.A., Wodicka L.M., Shah N.P., et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102 31 (2005) 11011-11016
91. Petti F., Thelemann A., Kahler J., et al. Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930. Mol Cancer Ther 4 8 (2005) 1186-1197
92. Garton A.J., Crew A.P.A., Franklin M., et al. OSI-930: a novel selective inhibitor of kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. Cancer Res 66 2 (2006) 1015-1024
93. Daley T., Metcalfe D.D., and Akin C. Association of the Q576R polymorphism in the interleukin-4 receptor alpha chain with indolent mastocytosis limited to the skin. Blood 98 3 (2001) 880-882
94. Sotlar K., Horny H.-P., Simonitsch I., et al. CD25 indicates the neoplastic phenotype of mast cells-a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 28 10 (2004) 1319-1325
95. Eklund J.W., and Kuzel T.M. Denileukin diftitox: a concise clinical review. Expert Rev Anticancer Ther 5 1 (2005) 33-38
96. Fumo G., Akin C., Metcalfe D.D., et al. 17-Allyamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 103 3 (2004) 1078-1084
97. Tanaka A., Konno M., Muto S., et al. A novel NF-κB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 105 6 (2005) 2324-2331
98. Cerveró C., Escribano L., San Miguel J.F., et al. Expression of bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia. Am J Hematol 60 3 (1999) 191-195
99. Santos D.D., Hatjiarissi E., Tournilhac O., et al. CD52 is expressed on human mast cells and is a therapeutic target for the anti-CD52 monoclonal antibody Campath-1H in Waldenstrom's macroglobulinemia and mast cell disorders. Blood 104 11 (2004) 304b
100. Kondo R., Mayerhofer M., Gleixner K., et al. Heme-oxygenase-1 (HO-1): a novel kit D816V-dependent target in neoplastic human mast cells (HMC-1). Blood 106 11 (2005) 983a
101. Boehm A., Florian S., Gleixner K., et al. Inhibition of growth of neoplastic mast cells by CD44 mAb A3D8 is associated with G1 cell cycle arrest and apoptosis. Blood 106 11 (2005) 982a
102. Aichberger K.J., Mayerhofer M., Gleixner K.V., et al. Identification of Mcl-1 as a novel target in neoplastic mast cells and demonstration of cooperative growth-inhibitory effects of mcl-1 antisense oligonucleotides, PKC412, and AMN107. Blood 106 11 (2005) 982a
103. Demehri S., Corbin A.S., Loriaux M., et al. Murine model of aggressive systemic mastocytosis: a disease caused by oncogenic kit. Blood 104 11 (2004) 666a-667a